The incidence of malignancy may be higher in elderly patients, particularly those with rheumatoid arthritis (RA) or myelodysplastic syndrome, as well as in individuals receiving prolonged therapy with tofacitinib or ruxolitinib (oral JAK inhibitors) or anti-TNF agents. Here, TNF is linked to rheumatoid arthritis.